Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

Nimotuzumab:

  • Daiichi Sankyo, CIMYM's licensee for nimotuzumab in Japan, previously initiated a randomized trial with the EGFR-targeting humanized monoclonal antibody in second line gastric cancer together with Kuhnil Pharma Co. Ltd., CIMYM's licensee in Korea, which they report completed recruitment in calendar 2009. Daiichi also launched a Phase II trial in first-line NSCLC for which YM has been advised that recruitment has been completed. Reports on both trials are expected during the first half of calendar 2011 as data mature. Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported safety data from a Phase III trial in adult glioma patients at ASCO 2010 and OSAG continues to recruit patients into a Phase IIb/III trial in pancreatic cancer patients. We are now advised by OSAG that data from the adult glioma trial may be released in the first half of 2011.

  • YM's two randomized, Phase II, double-blind trials of nimotuzumab (for brain metastasis from non-small cell lung cancer and for palliative stage NSCLC) are lagging recruitment targets and consequently these programs are under review as the Company focuses support on the more advanced trials involving Daiichi Sankyo which have the prospect of earlier registration trial initiation. YM's Phase II, second-line, single-arm study in children with progressive diffuse intrinsic pontine glioma (DIPG) has concluded recruitment at multiple sites in the US, Canada, and Israel and should report results prior to the end of calendar 2010.
  • CYT997:

  • Phase I clinical trial results for CYT997 were published in the premier cancer journal, the British Journal of Cancer, demonstrating that CYT997 was well tolerated at doses that were associated with evidence of vascular disruption in tumors. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity currently in a Phase II trial for glioblastoma
    '/>"/>

  • SOURCE YM BioSciences Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
    2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
    3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
    4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
    6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
    8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500â„¢
    9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
    10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
    11. Cell Biosciences to Acquire Convergent Bioscience
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... July 24, 2014 -- A novel combination of microscopy ... of Energy,s Oak Ridge National Laboratory an unprecedented look ... unusual physical and electrochemical properties. , The research ... affects the surface of a perovskite manganite, a complex ... new avenue to understand surface behavior could benefit researchers ...
    (Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
    (Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
    (Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
    Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
    ... and scale of EDS services allow Bristol-Myers Squibb to ... focus on core biopharmaceutical business, ... million information technology (IT) services contract that,calls for EDS to ... scope and scale will allow the company to,improve productivity so ...
    ... SpectraScience, Inc. (OTC,Bulletin Board: SCIE) announced today that ... of Finance and Chief Financial Officer., Jim Hitchin ... many years of,experience in public medical device, manufacturing and ... 25 years ago. With a graduate,degree in accounting, he ...
    ... Dec. 10 iCAD, Inc. (Nasdaq:,ICAD), an industry-leading ... identification of cancer, today announced that two,U.S. Patents, ... granted,to the Company by the United States Patent ... our on-going commitment to broadening,and protecting our intellectual ...
    Cached Biology Technology:EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 2EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 3Jim Dorst Joins SpectraScience as CFO 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 3
    (Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
    (Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
    (Date:7/24/2014)... 45% on average over a 35 year period in ... the impact of humans on declining animal numbers. This ... as insects, spiders, crustaceans, slugs and worms bring to ... crops, decomposition for nutrient cycling, water filtration and human ... and led by UCL, Stanford and UCSB, focused on ...
    Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
    ... working in College of Life Science, Zhejiang University, has ... CpG island has a parental differentially methylated region (DMR). ... imprinting exists in lower vertebrates and genomic imprinting should ... mammals. The study is reported in volume 54 (Issue ...
    ... A team of University of Oregon biologists, using fruit ... specific cells, opening a new window on how gene ... While DNA (deoxyribonucleic acid) provides an identical genetic blueprint ... that turn protein molecules on and off in different ...
    ... is the latest American Chemical Society (ACS) Weekly PressPac ... from ACS, 34 peer-reviewed journals and Chemical & Engineering ... Society as the source for this information. ... melamine-adulterated food , Journal of Agricultural and Food ...
    Cached Biology News:The evolutionary foundation of genomic imprinting in lower vertebrates 2New tool isolates RNA within specific cells 2American Chemical Society's Weekly PressPac -- May 13, 2009 2American Chemical Society's Weekly PressPac -- May 13, 2009 3American Chemical Society's Weekly PressPac -- May 13, 2009 4American Chemical Society's Weekly PressPac -- May 13, 2009 5American Chemical Society's Weekly PressPac -- May 13, 2009 6American Chemical Society's Weekly PressPac -- May 13, 2009 7American Chemical Society's Weekly PressPac -- May 13, 2009 8American Chemical Society's Weekly PressPac -- May 13, 2009 9American Chemical Society's Weekly PressPac -- May 13, 2009 10
    hnRNP U (H-94)...
    ... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
    ... causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your ... market it internationally. We work under ISO ...
    ... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
    Biology Products: